Log inSign up
AAOIFI No. 21 screening

Is AGMB halal?

AgomAb Therapeutics NV

Not halal

AgomAb Therapeutics NV did not pass AAOIFI screening. The failed check is shown below.

Checked: 13 October 2026

Exchange

NASDAQ

Price

8.28

Day

-0.60%

Market cap

$447.7M

Industry

Biotechnology

Sector

Healthcare

What the company does

AgomAb Therapeutics (Belgium) develops antibody drugs for inflammatory bowel disease and fibrosis (AGMB-129 for Crohn's), in clinical trials. No revenue.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $1.27M ÷ current market cap $447.66M = 0.3%

    0.3%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $282.05M ÷ current market cap $447.66M = 63.0%

    63.0%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict.

For information (AAOIFI 3/1 note): cash + receivables are 78.5% of total assets (2025-12-31). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.